Legend Biotech Corp

Legend Biotech Corporation announced the pricing of an underwritten public offering of 7,700,000 American Depositary Shares (ADSs) at $29.35 per ADS. Each ADS represents two ordinary shares. The company expects gross proceeds of approximately $226 million, before deducting underwriting discounts and commissions and estimated offering expenses. Underwriters have a 30-day option to purchase up to an additional 1,155,000 ADSs. The offering is anticipated to close on June 23, 2026, with Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities serving as joint book-running managers.

Legend Biotech Corporation has announced the commencement of an underwritten public offering to sell $225 million of American Depositary Shares (ADSs). The company will offer all ADSs, with underwriters holding a 30-day option to purchase an additional 15% of the ADSs sold. The offering is being managed by Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities as joint book-running managers.

Legend Biotech announced positive first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). In an ongoing Phase 1 study, LB2501 achieved a 100% objective response rate (ORR) and an 83.3% complete response (CR) rate at the higher dose level (DL2) following a single infusion, with all responses ongoing. The therapy demonstrated dose-dependent CAR-T expansion without lymphodepletion and a favorable safety profile, reporting no dose-limiting toxicities, serious adverse events, ICANS, or deaths. These results were presented at the EHA 2026 Congress, highlighting the company's progress in next-generation cell therapies.

Legend Biotech announced positive first clinical proof-of-concept data for its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, LB2501, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The Phase 1 study showed a 100% objective response rate (ORR) and an 83.3% complete response rate (CR) at the higher dose level (DL2), with all responses ongoing. The therapy demonstrated a favorable safety profile with no dose-limiting toxicities, serious adverse events, or deaths reported. These results support the potential of LB2501 as a first-in-class therapy.

Legend Biotech announced positive first clinical proof-of-concept data for LB2501, its investigational in vivo CD19/CD20 dual-targeting CAR-T cell therapy, in a Phase 1 study for relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). At the higher dose level (DL2), LB2501 achieved a 100% objective response rate and an 83.3% complete response rate, with all responses ongoing. The therapy demonstrated a favorable safety profile with no dose-limiting toxicities or serious adverse events, and dose-dependent CAR-T expansion without lymphodepletion.

Legend Biotech announced promising preliminary clinical data for its investigational in vivo CAR-T cell therapy, LB2501, for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The data, to be presented at EHA 2026, showed a 100% objective response rate (ORR) and 83.3% complete response rate (CR) in the dose level 2 cohort. The therapy demonstrated a favorable safety profile with no DLTs, SAEs, or ICANS, and showed robust in vivo CAR-T expansion.

Legend Biotech presented first-in-human clinical data for LB2102, its investigational DLL3-targeted CAR-T cell therapy for relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC), at ASCO 2026. The data showed early evidence of clinical activity with an objective response rate of 20% and a manageable safety profile. Additionally, new analyses from the CARTITUDE program reinforced the durable efficacy and consistent safety profile of CARVYKTI ® (ciltacabtagene autoleucel) in multiple myeloma, which has now treated over 10,000 patients globally.

Legend Biotech announced it will present new data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. This includes preliminary Phase 1 data for LB2102, its investigational CAR-T therapy for relapsed or refractory small-cell lung cancer (SCLC) and large-cell neuroendocrine carcinoma (LCNEC), and new data on CARVYKTI® (ciltacabtagene autoleucel) from the CARTITUDE program. The company will also host a live webcast event for investors on May 31, 2026, to discuss CARVYKTI's impact on multiple myeloma treatment.

Legend Biotech announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, including preliminary Phase 1 data for LB2102, its investigational DLL3-targeted CAR-T therapy for relapsed or refractory small-cell lung cancer and large-cell neuroendocrine carcinoma. The data highlights a manageable safety profile and early evidence of clinical activity, marking progress in extending CAR-T approaches into solid tumors. Additionally, new analyses of CARVYKTI® from the CARTITUDE-4 study and on immune effector cell-associated enterocolitis will be presented, reinforcing its robust clinical profile in multiple myeloma. The company will also host an investor relations event during ASCO.

Legend Biotech reported strong first quarter 2026 results, driven by a 62% increase in CARVYKTI net trade sales to $597 million. The company expanded CARVYKTI's global availability to 18 markets with recent launches in Italy, Poland, the Czech Republic, and Australia. Legend Biotech significantly narrowed its net loss to $54.3 million and adjusted net loss to $10.5 million, reflecting improved operating performance and progress towards sustainable profitability beyond 2026.